Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Current Assets (2022 - 2025)

Jin Medical International (ZJYL) has disclosed Current Assets for 4 consecutive years, with $44.1 million as the latest value for Q3 2025.

  • Quarterly Current Assets rose 3.1% to $44.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $44.1 million through Sep 2025, up 3.1% year-over-year, with the annual reading at $44.1 million for FY2025, 3.1% up from the prior year.
  • Current Assets hit $44.1 million in Q3 2025 for Jin Medical International, up from $42.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $44.1 million in Q3 2025 to a low of $18.9 million in Q3 2022.
  • Historically, Current Assets has averaged $34.2 million across 4 years, with a median of $37.0 million in 2023.
  • Biggest five-year swings in Current Assets: skyrocketed 64.61% in 2023 and later grew 3.1% in 2025.
  • Year by year, Current Assets stood at $18.9 million in 2022, then soared by 64.61% to $31.1 million in 2023, then surged by 37.6% to $42.8 million in 2024, then increased by 3.1% to $44.1 million in 2025.
  • Business Quant data shows Current Assets for ZJYL at $44.1 million in Q3 2025, $42.8 million in Q3 2024, and $31.1 million in Q3 2023.